Oxandrolone in the Treatment of HIV-Associated Weight Loss in Men: A Randomized, Double-Blind, Placebo-Controlled Study

@article{Grunfeld2006OxandroloneIT,
  title={Oxandrolone in the Treatment of HIV-Associated Weight Loss in Men: A Randomized, Double-Blind, Placebo-Controlled Study},
  author={C. Grunfeld and D. Kotler and A. Dobs and M. Glesby and S. Bhasin},
  journal={JAIDS Journal of Acquired Immune Deficiency Syndromes},
  year={2006},
  volume={41},
  pages={304-314}
}
  • C. Grunfeld, D. Kotler, +2 authors S. Bhasin
  • Published 2006
  • Medicine
  • JAIDS Journal of Acquired Immune Deficiency Syndromes
  • Objective: To evaluate the efficacy and safety of oxandrolone in promoting body weight and body cell mass (BCM) gain in HIV-associated weight loss. Methods: Randomized, double-blind, placebo-controlled trial. Two hundred sixty-two HIV-infected men with documented 10% to 20% weight loss or body mass index ≤20 kg/m2 were randomized to placebo or to 20, 40, or 80 mg of oxandrolone daily. After 12 weeks, subjects were allowed to receive open-label oxandrolone at a dose of 20 mg for another 12 weeks… CONTINUE READING
    Androgen deficiency: effects on body composition
    25

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 83 REFERENCES
    Treatment with oxandrolone and the durability of effects in older men.
    32